Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verasone Phase 1 SAD/MAD in Healthy Volunteers
NCT06147921Phase 1Completed
- Sponsor
- Diceros Therapeutics
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Verasone in chronic rhinosinusitis (CRS) (7 arms), sponsored by Diceros Therapeutics. Primary endpoints: Safety and Tolerability at 3 weeks and Pharmacokinetics at 3 weeks. Started Dec 2023; status: completed.
02
Drugs
Verasone
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on NCT06147921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06147921.